Teamwork Financial Advisors LLC Trims Stake in Danaher Co. (NYSE:DHR)

Teamwork Financial Advisors LLC trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 58.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,124 shares of the conglomerate’s stock after selling 1,580 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Danaher were worth $258,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Decker Retirement Planning Inc. acquired a new stake in shares of Danaher during the fourth quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the third quarter worth $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC purchased a new position in Danaher in the third quarter valued at $55,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Up 0.0 %

Shares of NYSE:DHR opened at $244.19 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a market cap of $176.38 billion, a P/E ratio of 46.60, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70. The firm has a fifty day moving average price of $234.90 and a 200 day moving average price of $253.47.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company posted $2.02 earnings per share. Sell-side analysts predict that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Evercore ISI upped their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup reduced their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Barclays dropped their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a report on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.